文献速递急性肾损伤

SIRPα胞外囊泡经CD47重编程循环髓系细胞治疗急性肾损伤

Therapeutic reprogramming of circulating myeloid cells via signal regulatory protein α extracellular vesicles in acute kidney injury.
PubMed 文献 · Kidney Int · 2025-12-23

该研究通过单细胞RNA测序和CD47染色发现,人及小鼠急性肾损伤(AKI)中髓系细胞(尤其巨噬细胞)CD47表达显著升高。研究者构建高亲和力SIRPα变体胞外囊泡(SIRP-EVs),在小鼠AKI模型中单次全身给药可改善肾功能指标、减少促炎因子并减轻组织病理,机制为靶向循环髓系细胞、抑制其向损伤肾脏迁移并重编程为促修复表型。

要点

  • AKI时髓系细胞CD47表达升高,是潜在治疗靶点。
  • SIRP-EVs单次给药在小鼠AKI中改善肾功能与病理。
  • SIRP-EVs靶向循环髓系细胞,抑制迁移并促修复重编程。

核心结论

  • 靶向循环髓系细胞CD47的SIRP-EVs是一种先于组织浸润的全身免疫调节策略,有望治疗AKI。

研究设计与样本

  • 研究采用单细胞RNA测序和CD47蛋白染色分析人AKI标本及顺铂和双侧缺血再灌注两种小鼠模型。
  • 工程化人骨髓间充质干细胞来源胞外囊泡表达高亲和力SIRPα变体(SIRP-EVs),在小鼠AKI模型中评估疗效。

主要发现

  • CD47在人AKI组织和小鼠模型的髓系群体尤其巨噬细胞中显著升高。
  • 小鼠AKI模型中单次全身给予SIRP-EVs改善肾功能标志物、减少促炎因子产生并改善肾脏组织病理。
  • SIRP-EVs优先定位至循环髓系细胞,调节CD47表达并抑制其迁移至损伤肾组织。
  • 单细胞转录组显示SIRP-EV治疗使循环巨噬细胞重编程为促修复表型,上调组织修复相关基因。

临床怎么用

  • SIRP-EVs通过选择性调节和外周髓系细胞重编程,为AKI提供潜在全身治疗选项。
  • 该策略先于组织浸润发挥作用,有别于传统以组织为中心的方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Acute kidney injury (AKI) presents significant clinical challenges, with high mortality and progression risk to chronic kidney disease. Mechanisms remain incompletely understood and disease-specific therapies are lacking. Recent evidence highlights the pivotal role of infiltrating myeloid cells in perpetuating kidney inflammation. CD47, a key cell surface immune checkpoint protein, is upregulated in inflammation and regulates myeloid cell infiltration, making it an attractive therapeutic target. METHODS: Single-cell RNA sequencing and CD47 protein staining were used to identify CD47 expressions in human AKI specimens and two mouse models (cis-platin and bilateral ischemia/reperfusion). To therapeutically exploit this, we engineered extracellular vesicles (EVs) from human bone marrow mesenchymal stem cells to express a high-affinity signal regulatory protein a (SIRPα) variant (SIRP-EVs), the ligand for CD47. The efficacy of SIRP-EVs was evaluated in murine AKI models. RESULTS: CD47 expression was significantly elevated in myeloid populations, particularly macrophages, in both human AKI tissues and mouse models. A single systemic administration of SIRP-EVs in murine AKI models exhibited therapeutic effects, including improved kidney function markers, reduced pro-inflammatory cytokine production, and ameliorated kidney histopathology. Mechanistically, SIRP-EVs preferentially localize to circulating myeloid cells, modulate CD47 expression, and subsequently inhibit their migration into injured kidney tissue. Moreover, single cell transcriptomics revealed that SIRP-EV treatment reprograms circulating macrophages toward pro-resolving phenotypes, characterized by upregulation of genes associated with tissue repair. CONCLUSIONS: Targeting CD47 on circulating myeloid cells with SIRP-EVs provides a systemic, blood-focused immunomodulatory strategy that precedes tissue infiltration, contrasting with conventional tissue-centric approaches. Our findings support SIRP-EVs as a promising therapeutic option for AKI and potentially other inflammation-driven diseases through selective modulation and reprogramming of peripheral myeloid cells.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Shin DU, Jo MK, Kwon M, et al. Therapeutic reprogramming of circulating myeloid cells via signal regulatory protein α extracellular vesicles in acute kidney injury. Kidney Int. 2025. PMID: 41448459. doi:10.1016/j.kint.2025.12.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。